君实生物今日盘中大涨5.43%，引起了市场的广泛关注。
消息面上，公司此前公告第三大股东上海檀英投资减持计划期满，期间未减持任何股份，向市场释放了积极信号。同时，公司年度业绩显示全年营收同比增长28.23%，核心产品特瑞普利单抗销售收入增长超40%，并已在全球40多个国家和地区获批上市。
此外，创新药板块近日整体情绪回暖，君实生物作为板块代表个股受益于此。公司PD-1/VEGF双抗、EGFR/HER3 ADC等多款研发管线持续推进，也进一步提升了市场关注度。
君实生物今日盘中大涨5.43%，引起了市场的广泛关注。
消息面上，公司此前公告第三大股东上海檀英投资减持计划期满，期间未减持任何股份，向市场释放了积极信号。同时，公司年度业绩显示全年营收同比增长28.23%，核心产品特瑞普利单抗销售收入增长超40%，并已在全球40多个国家和地区获批上市。
此外，创新药板块近日整体情绪回暖，君实生物作为板块代表个股受益于此。公司PD-1/VEGF双抗、EGFR/HER3 ADC等多款研发管线持续推进，也进一步提升了市场关注度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.